


THE COST SAVINGS POTENTIAL OF PROVANT THERAPY IN THE TREATMENT OF FAILED BACK SURGERY SYNDROME PAIN

June 2015 Newsletter

Given the high volume of lumbar spine surgeries and a persistent pain incidence rate as high as 46%, the burden of failed back surgery syndrome on healthcare system cost is significant. Although spinal cord stimulation devices and re-operation have not demonstrated superior effectiveness, they are associated with significantly higher two-year costs.

The results of an open label, multicenter study of Provant Therapy demonstrate that there is potential for cost savings in this patient population. The two-year potential savings over standard of care is significant at \$18,817. This is based upon avoidance of costly procedures.



You may read the full paper [here](#).

Did you know?Over 11,000 patients have now benefited from non-narcotic Provant Therapy. The complete body of clinical evidence for Provant may be found [here](#). To learn more how RegenesiS Biomedical may help your patients and you, please contact your local representative, or visit www.regenesibio.com

If you have colleagues that would like to receive these monthly newsletters, please forward this email to them; they may subscribe by emailing us at newsletter@regenesibio.com

Sincerely,



Adrienne (Patti) Smith, MD
Vice President, Clinical Business and Education
patti.smith@regenesibio.com